Physician Liver Function Test (LFT) Monitoring for Tykerb Pts
Assessment of Physician Compliance to Recommended Liver Function Test Monitoring for Tykerb Patients
In July 2008, the lapatinib (Tykerb) Prescribing Information (label) was updated to include a boxed warning related to hepatotoxcity and detailed instructions for monitoring liver function before and during lapatanib exposure. For patient safety, it is of interest to know the extent to which providers are adherent with these guidelines for hepatic monitoring of lapatanib users.
Thus, the aim of this study is to determine if physicians conduct liver function testing prior to prescribing lapatanib and at regular intervals during exposure, and if they withdraw lapatanib, and do not re-treat, for patients who demonstrate severe liver enzyme elevations while exposed. These aims will be tested in the "Pre-label" (prior to the boxed warning) and "Post-label" (after the boxed warning) periods to determine if physician adherence to the guidelines changed as a result of the warning.
Specifically, the boxed warning provided the following guidance:
"Hepatotoxicity (alanine transaminase or aspartate transaminase >3 times the upper limit of normal and total bilirubin >1.5 times the upper limit of normal) has been observed in clinical trials (<1% of patients) and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain. The hepatotoxicity may occur days to several months after initiation of treatment. Liver function tests (transaminases, bilirubin, and alkaline phosphatase) should be monitored before initiation of treatment, every 4 to 6 weeks during treatment, and as clinically indicated. If changes in liver function are severe, therapy with lapatanib should be discontinued and patients should not be re-treated with lapatanib"
The following objectives will be assessed and compared among patients prescribed lapatanib before and after the addition of detailed guidance on liver function testing to the product label on July 9, 2008:
- Objective 1: Determine if physicians perform liver funtion tests (LFTs) prior to prescribing lapatanib (baseline)
- Objective 2: Describe the prevalence of LFT elevations at baseline
- Objective 3: Determine if physicians routinely perform LFTs during the duration of lapatanib exposure
- Objective 4: Describe the cumulative incidence and incidence rate of LFT elevations during lapatanib exposure
- Objective 5: Describe patients that experience severe LFT elevations during lapatanib exposure and calculate the proportion that have lapatanib discontinued and are not re-treated
To achieve these objectives, an observational retrospective cohort study will be conducted using the United States Oncology Electronic Medical Records database. The study population will consist of females with a diagnosis of metastatic breast cancer and a documented order for Lapatanib from January 1, 2007 - December 31, 2009. Patients will be categorized by whether they initiated Lapatanib before or after the July 9, 2008 label change.
'Pre Label': Initiated lapatanib between January 1, 2007 and December 31, 2007. Follow-up time for this group will continue until June 30, 2008 to allow these patients to have at least six months of follow-up time prior to the label change.
'Post Label': Initiated lapatanib between July 9, 2008 and December 31, 2009. Follow-up time for this group will continue until June 30, 2010 to allow these patients to have at least six month of follow-up.
The exposure in this study is lapatanib oral medication. The date of initiation of lapatanib will be the index date. Lapatanib exposure period(s) will be defined from the index date through to the end of the study period (June 30, 2008 for pre-label group or June 30, 2010 for post-label group).
The project will use proportions and two estimates of incidence (cumulative incidence and incidence rates using person-time) to describe the outcomes of interest among the users of Lapatanib before and after the label change. The following LFTs will be considered:
- alanine transaminase (ALT)
- aspartate transaminase (AST)
- alkaline phosphatise (ALP)
調査の概要
研究の種類
入学 (実際)
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Female aged >= 19 years
- A diagnosis of breast cancer with documented metastatic disease (as defined by stage at diagnosis, evidence of disease progression, and/or line of therapy);
- Documented order/prescription for lapatanib from January 1, 2007 - December 31, 2009;
- Received care at a practice utilizing the full electronic medical record capabilities of US Oncology's iKnowMed system
Exclusion Criteria:
- Patients participating in clinical trials
- Patients receiving care for another cancer during the study time period
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:コホート
- 時間の展望:回顧
コホートと介入
グループ/コホート |
介入・治療 |
---|---|
Metastatic breast cancer pre-label group
Patients with metastatic breast cancer who initiated lapatanib between January 1, 2007 and December 31, 2007.
Follow-up time for this group will continue until June 30, 2008 to allow these patients to have at least six months of follow-up time prior to the label change.
|
Prescription of lapatinib (Tykerb)
|
Metastatic breast cancer post-label group
Patients with metastatic breast cancer who initiated lapatanib between July 9, 2008 and December 31, 2009.
Follow-up time for this group will continue until June 30, 2010 to allow these patients to have at least six month of follow-up.
|
Prescription of lapatinib (Tykerb)
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
The change in proportion of patients that receive liver function tests prior to the initiation of lapatanib
時間枠:Within 30 days, 60 days, or 90 days prior to (and including) the day that lapatanib was initiated
|
Within 30 days, 60 days, or 90 days prior to (and including) the day that lapatanib was initiated
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
The change in prevalence of LFT elevations prior to the initiation of lapatanib
時間枠:Within 30 days, 60 days or 90 days prior to (and including) the day that lapatanib was initiated
|
Within 30 days, 60 days or 90 days prior to (and including) the day that lapatanib was initiated
|
The proportion of patients that have LFT performed routinely (at least every 6 weeks) while exposed to lapatanib
時間枠:During entire lapatanib exposure (Based on index date between January 2007 - June 2010).
|
During entire lapatanib exposure (Based on index date between January 2007 - June 2010).
|
The incidence of LFT elevations while exposed to lapatanib
時間枠:During entire lapatanib exposure (Based on index date between January 2007 - June 2010).
|
During entire lapatanib exposure (Based on index date between January 2007 - June 2010).
|
The proportion of patients with a severe LFT elevation that have lapatanib withdrawn, and are not re-treated
時間枠:During entire lapatanib exposure (Based on index date between January 2007 - June 2010).
|
During entire lapatanib exposure (Based on index date between January 2007 - June 2010).
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 115270
- WEUKSTV4275 (その他の識別子:GSK)
- EPI40640 (その他の識別子:GSK)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
癌の臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ